|Day Low/High||4.14 / 4.20|
|52 Wk Low/High||2.15 / 5.78|
US stocks rise as commodities prices rally, dollar stays near recent lows; industrials climb
The weight-loss results were impressive from two pivotal studies of Vivus' obesity drug Qnexa.
Vivus' obesity drug candidate hits weight reduction goals in 2 late-stage studies; shares soar
Vivus says it will announce data from 2 clinical trials of obesity drug candidate Qnexa
Investor conferences and phase III data on tap for post-Labor Day
Taking advantage of this seasonally slow period to take a closer look at some potential names for the model portfolio.
Earnings roundup: Clearwire 2Q loss shrinks, Celadon Group 4Q profit drops 92 percent
Guests include TheStreet.com Breakout Stocks editor Bryan Ashenberg, TheStreet.com Stocks Under $10 editor David Peltier and RealMoney.com contributor Don Dion.
Researching biopharmaceutical names in the anti-obesity drug sector as potential additions to the model portfolio.
Obesity patients treated with a weight-loss combination pill from Orexigen Therapeutics lost an average of more than 13 pounds, or just more than 6% of their body weight, after one year of treatment, studies show.
Another quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.
Earnings roundup: Fossil 1Q net down, but hikes full-year outlook; Vivus 1Q loss shrinks
Vivus posts smaller 1st-quarter loss on lower development costs for obesity drug candidate
Arena Pharmaceuticals reported phase III trial data for obesity drug lorcaserin that did not hit all FDA standards.
Arena Pharmaceuticals shares drop as obesity drug falls shy of a proposed FDA benchmark
Arena fans take issue with a column outlining the company's challenges.
Drug company Arena Pharmaceuticals is under pressure to produce stellar results from a phase III study of its obesity drug later this month.
Inergy is upgraded; Chubb, CB Richard Ellis Group, Equity Residential and CNA Financial are downgraded.
Vivus posts 4th-quarter loss after doubling research spending as Qnexa trials continue
Obesity patients treated with a weight-loss pill from Orexigen Therapeutics lost an average of 20.3 pounds, or 9.3% of their body weight, over one year, according to results from a phase III study released Thursday.
Orexigen Therapeutics is expected to release the first phase III data on its experimental weight-loss drug Contrave ahead of a key investor presentation Monday.
Phase III study shows patients treated with a high dose of Qnexa lost 7.5% of their body weight adjusted for placebo.
Scores of smaller biotech firms have unpartnered drugs in the pipeline, making them ripe for alliances or takeovers.
The drugmaker is losing three executives and ending two trials weeks before it releases results of a pivotal obesity drug study.
The pending results from two studies of Vivus' drug Qnexa is just the start of what promises to be an active 12 months in the race to develop the next generation of obesity drugs.
The regulatory agency is alerting diabetes-drug makers, like Amylin, of new heart-safety data standards.
Xoma's promising study results on a diabetes drug makes it more likely it will find a partner.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.